The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Simulations Plus imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the ...

The transaction, valued at roughly $100 million in cash, signifies a strategic move for Simulations Plus in augmenting its footprint across the drug development continuum, from pre-clinical protocols to product commercialization. The acquisition solidifies Simulation Plus' portfolio, bolstering its scientific skills, drug development expertise, data management acumen, predictive analytics and biosimulation capabilities. Simulation Plus is a well-known name in the biosimulation market and consulting services ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 29, 2024 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-32046 Simulations Plus, Inc. (State or other jurisdiction of Incorporation or Organization) (I.R.S. Emplo ...

2Q24 PBPK QSP CPP REG Backlog $18.0 $17.0 $15.4 2Q22 2Q23 2Q24 17 Income Statement Summary - Q2 FY24 (in millions, except Diluted EPS) | --- | --- | --- | --- | --- | |----------------------------|-------|----------|-------|----------| | | 2Q24 | % of Rev | 2Q23 | % of Rev | | Revenue | $18.3 | 100% | $15.8 | 100% | | Revenue growth | 16% | | 6% | | | Gross profit | 13.2 | 72% | 13.1 | 83% | | R&D | 1.3 | 7% | 1.3 | 8% | | S&M | 1.9 | 11% | 1.7 | 11% | | G&A | 5.5 | 30% | 6.0 | 38% | | Total operating exp | ...

Simulations Plus, Inc. (NASDAQ:SLP) Q2 2023 Results Earnings Conference Call April 4, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer and Chief Operating Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group David Larsen - BTIG LLC François Brisebois - Oppenheimer & Co. Inc. Operator Greetings. And welcome to the Simulations Plus Second Quarter Fiscal 2024 F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2023 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-32046 Simulations Plus, Inc. (Name of registrant as specified in its charter) California 95-4595609 (Stat ...

Simulations Plus, Inc. (NASDAQ:SLP) Q1 2024 Earnings Conference Call January 3, 2024 5:00 PM ET Company Participants Tamara Gonzalez - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer and Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group David Larsen - BTIG François Brisebois - Oppenheimer Operator Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2024 Financial Results Confe ...

2 CURRENT PERIOD | --- | --- | --- | --- | |------------------------------|-------------|-------------|---------| | | | | | | Prior Year Comparison (1Q23) | | | | | $12.0M | $0.06 | 25% | $15.8M | | Revenue | Diluted EPS | Adjusted | Backlog | | | | EBITDA as % | | | | | of Revenue | | GastroPlus® (Physiologically Based Pharmacokinetics) Q1 Revenue Growth General | --- | --- | |--------------------|-------------------------------------------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-32046 Simulations Plus, Inc. (Exact name of registrant as specified in its charter) California 95-4595609 (St ...

Simulations Plus, Inc. (NASDAQ:SLP) Q4 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Tamara Gonzales - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Matt Hewitt - Craig-Hallum David Larsen - BTIG David Windley - Jefferies Operator Greetings, and welcome to the Simulations Plus Fourth Quarter Fiscal 2023 Financial Results Conference Call. At ...